Tuesday, Jan 31, 1989
South San Francisco, Calif. -- January 31, 1989 --Genentech, Inc. today announced it will not appeal an unfavorable British Court of Appeals decision in its litigation with Wellcome PLC over the United Kingdom patent for recombinant tissue plasminogen activator (t-PA). The company said the doctrines applied in the British case will have no relevance in United States patent cases.
Genentech markets t-PA in North America under the trade name Activase, as a drug for dissolving blood clots that cause heart attacks. Genentech's United Kingdom marketing partner, Boehringer Ingelheim Ltd., received approval to market t-PA in the United Kingdom and other countries under the trade name Actilyse in 1987 and 1988. Genentech said the United Kingdom patent case involved only a minimal effect on royalties in that country.
Genentech, Inc. is a leading biotechnology company focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #